{"filing":{"accession_number":"0001079973-26-001006","cik":"0001799191","ticker":"TOIIW","company_name":"Starling Oncology, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"stln_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997326001006/stln_8k.htm"},"events":[{"id":24586,"run_id":22294,"accession_number":"0001079973-26-001006","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Starling Oncology issued a press release on August 6, 2026 announcing financial results for the three months ended June 30, 2026, including consolidated revenue of $161.3 million (up 34.6%), gross profit of $27.2 million (up 55.2%), and Adjusted EBITDA turning positive at $229 thousand. The company also updated full-year 2026 guidance, raising revenue guidance to $650–$670 million and gross profit guidance to $105–$110 million. This is a standard quarterly earnings release with material financial metrics and forward guidance.","company_name":"Starling Oncology, Inc.","ticker":"TOIIW","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":25193,"accession_number":"0001079973-26-001006","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Starling Oncology issued a press release on August 6, 2026 announcing financial results for the three months ended June 30, 2026, including consolidated revenue of $161.3 million (up 34.6%), gross profit of $27.2 million (up 55.2%), and Adjusted EBITDA turning positive at $229 thousand. The company also updated full-year 2026 guidance, raising revenue guidance to $650–$670 million and gross profit guidance to $105–$110 million. This is a standard quarterly earnings release with material financial metrics and forward guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:16:56.544652+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25193,"accession_number":"0001079973-26-001006","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Starling Oncology issued a press release on August 6, 2026 announcing financial results for the three months ended June 30, 2026, including consolidated revenue of $161.3 million (up 34.6%), gross profit of $27.2 million (up 55.2%), and Adjusted EBITDA turning positive at $229 thousand. The company also updated full-year 2026 guidance, raising revenue guidance to $650–$670 million and gross profit guidance to $105–$110 million. This is a standard quarterly earnings release with material financial metrics and forward guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:16:56.544652+00:00","company_name":"Starling Oncology, Inc.","ticker":"TOIIW","filing_date":"2026-08-06"}]}